(Total Views: 566)
Posted On: 06/05/2025 10:37:00 AM
Post# of 154633
"Pharma companies rush in to buy what they hope will rival Keytruda"
As mentioned previously, the race for PD-1/PD-L1 x VEGF bispecifics is heating up.
“I think this is harder than the PD-1 race, in that you have to compare to PD-1 alone,” Graybosch said, referring to Keytruda and other related drugs’ success as standards of care. “That’s a more challenging, formidable standard of care that you have to show benefit on top of.”
How to win
It’s too early to call any winners in a race that might not come down to speed, Graybosch said. Other strategies could involve using VEGF to extend PD-1’s benefit to new indications, or creating novel combinations.
Hello... seems to describe leronlimab perfectly.
As mentioned previously, the race for PD-1/PD-L1 x VEGF bispecifics is heating up.
“I think this is harder than the PD-1 race, in that you have to compare to PD-1 alone,” Graybosch said, referring to Keytruda and other related drugs’ success as standards of care. “That’s a more challenging, formidable standard of care that you have to show benefit on top of.”
How to win
It’s too early to call any winners in a race that might not come down to speed, Graybosch said. Other strategies could involve using VEGF to extend PD-1’s benefit to new indications, or creating novel combinations.
Hello... seems to describe leronlimab perfectly.
(11)
(0)
